Anton Vladić

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial

Alasdair Coles, Edward Fox, Anton Vladić et al. · Neurology · 2012 · 260 citations

Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis

Gilbert H. Daniels, Anton Vladić, Vesna Brinar et al. · The Journal of Clinical Endocrinology & Metabolism · 2013 · 146 citations

Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

Alasdair Coles, Edward Fox, Anton Vladić et al. · The Lancet Neurology · 2011 · 138 citations

Rheumatology, Clinical Efficacy Outcomes, Autoimmune Disease +9

Alemtuzumab long-term immunologic effect

Stefania De Mercanti, Simona Rolla, Angele Cucci et al. · Neurology Neuroimmunology & Neuroinflammation · 2016 · 73 citations · Full text

CEREBROSPINAL FLUID AND SERUM PROTEIN LEVELS OF TUMOUR NECROSIS FACTOR-ALPHA (TNF-α), INTERLEUKIN-6 (IL-6) AND SOLUBLE INTERLEUKIN-6 RECEPTOR (sIL-6R gp80) IN MULTIPLE SCLEROSIS PATIENTS

Anton Vladić, Gordana Horvat, Stjepan Vukadin et al. · Cytokine · 2002 · 56 citations

Inflammation, Tumour Necrosis Factor-alpha, Medicine +13